Safety & Feasibility of Remote Ischemic Conditioning on Prehypertension &

Status Recruiting

Clinical Trial Summary

Nowadays, the incidence of stroke in China has reached 1.6‰, and this disease has become a primary cause of death in China. One of its major risk factors is hypertension. As shown in the researches, the risk of stroke grows remarkably when the blood pressure increases and there exists a log-linear relationship between them. Systolic pressure and diastolic pressure relate to the risk of stroke independently. Systolic pressure decreasing 10mmHg will reduce the stroke risk by 31% and a decrease of 1~3mmHg will reduce the stroke risk by20~30%. As to diastolic pressure, a 5mmHg decrease will reduce the stroke risk by 34% and a 10mmHg decrease will reduce the stroke risk by 56%.In addition, patients with isolated systolic hypertension (SPB≥160mmHg, DPB≤90mmHg) or critical isolated systolic hypertension (SPB=140~159mmHg, DPB< 90mmHg) will suffer a higher risk of stroke than people with normal blood pressure. The ACC has already revised its Hypertension ManagementGuidelines of the standard of diagnosis for hypertension and the timing of starting medical treatment in hypertensive patients. Because more and more researches shown that people with blood pressure between 120-139/80-89mmHg have higher risk of ASCVSD compared to those with blood pressure lower than120/80mmHg; However, in China, the diagnostic criteria for hypertension has not been revised yet. Therefore, we still have a blind spot in treating such patients who suffer from borderline systolic hypertension at 130~140 mmHg of blood-pressure with or without ASCVD or those with the first stage hypertension but refusing to take anti-hypertension drugs. What is more, most of them are middle-aged adults, once they have a stroke, it would lead to terrible and costly consequences to both their family and society. Thus, it is necessary to explore new non-pharmacological methods to control blood pressure for reducing the risk of stroke

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04254432
Study type	Interventional
Source	Capital Medical University
Contact	yu gao
Phone	8613051119757
Email	yingmudao1990@gmail.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	June 30, 2019
Completion date	March 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03644524` - Heat Therapy and Cardiometabolic Health in Obese Women	N/A
Completed	`NCT02551640` - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients	N/A
Recruiting	`NCT01483430` - Effect of Ginseol Kg1 on Blood Pressure Lowering	Phase 3
Completed	`NCT01637909` - Korean Life-Style Modification Effects on Blood Pressure	N/A
Terminated	`NCT01295216` - Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings	N/A
Unknown status	`NCT01308983` - Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension	Phase 4
Active, not recruiting	`NCT03596099` - Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10%	N/A
Completed	`NCT04326686` - Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension	N/A
Completed	`NCT03898518` - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls	N/A
Terminated	`NCT01983462` - Vascular Dysfunction in Human Obesity Hypertension	Phase 2
Completed	`NCT01458496` - Health Coaching to Effect Lifestyle Behaviour Change	N/A
Completed	`NCT01472692` - Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure	Phase 4
Completed	`NCT03266510` - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function	N/A
Completed	`NCT02998840` - A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure	Phase 2
Completed	`NCT01974570` - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects	Phase 2
Completed	`NCT02326766` - Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects	Phase 3
Completed	`NCT01395329` - Nebivolol and the Endothelin (ET)-1 System	Phase 4
Completed	`NCT01331486` - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract	Phase 1
Completed	`NCT05274971` - Diet and Exercise on Ambulatory Blood Pressure	N/A
Active, not recruiting	`NCT02371317` - Stress Management for High Blood Pressure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Feasibility of Remote Ischemic Conditioning on Prehypertension and Early-stage Hypertension

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms